Linfoma della zona grigia

Bibliografia

1.     Definizione di malattia e implicazioni classificative

Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022; 140: 1229-1253

2.     Aspetti anatomopatologici e di biologia molecolare

Sarkozy C, Copie-Bergman C, Damotte D, et al. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA. Am J Surg Pathol, 2019; 43: 341-351.

Pittaluga S, Nicolae A, Wright GW, et al. Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. Blood Cancer Discov, 2020; 1: 155-161.

Sarkozy C, Hung SS, Chavez EA, et al. Mutational landscape of gray zone lymphoma. Blood, 2021; 137: 1765-1776.

Pilichowska M, Pittaluga S, Ferry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv, 2017; 1: 2600-2609.

3.     Terapia di prima linea

Evens A, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol, 2015; 90: 778-783.

Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood, 2014; 124: 1563-1569.

Sarkozy C, Molina T, Ghesquières H, et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica, 2017; 102: 150-159.

4.     Ruolo del trapianto autologo in prima remissione e in salvataggio

Kharfan-Dabaja MA, Raj R, Nikolaenko L, et al. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant, 2017; 24: 486-493.

5.     Terapia della malattia in ricaduta e refrattaria: ruolo dei checkpoint inibitori, da soli e in combinazione

Melani C, Major A, Schowinsky J, et al. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med, 2017; 377: 89-91.

Santoro A, Moskowitz AJ, Ferrari S, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma. Blood, 2023; 141: 2780-2783.